Literature DB >> 35738613

Prognostic Factors for Complete Recovery From Xerostomia After Radiotherapy of Head-and-Neck Cancers.

Dirk Rades1, Britta Warwas2, Karsten Gerull2, Ralph Pries3, Anke Leichtle3, Karl L Bruchhage3, Samer G Hakim4, Steven E Schild5, Florian Cremers2.   

Abstract

BACKGROUND/AIM: Radiotherapy of head-and-neck cancers can cause xerostomia. This study investigated potential prognostic factors for complete recovery from this complication. PATIENTS AND METHODS: Eighty head-and-neck cancer patients with radiation-induced xerostomia were retrospectively evaluated. Thirteen characteristics were analyzed for complete recovery (to grade 0) from xerostomia including age, sex, tumor site and stage, nodal stage, upfront surgery, mean dose to ipsilateral, contralateral and both parotid glands, chemotherapy, radiation type and dose, and initial grade of xerostomia.
RESULTS: Fifteen patients (18.8%) experienced complete recovery of xerostomia. Significant associations with complete recovery were found for initial grade 1 xerostomia (p<0.001), mean dose to contralateral parotid gland of <20 Gy (p=0.034), and radiation treatment without chemotherapy (p=0.047).
CONCLUSION: Almost every fifth patient experienced complete recovery of xerostomia. Prognostic factors were identified that can guide radiation oncologists during the process of treatment planning.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Head-and-neck cancer; complete recovery; prognostic factors; radiotherapy; xerostomia

Mesh:

Year:  2022        PMID: 35738613      PMCID: PMC9301398          DOI: 10.21873/invivo.12894

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  31 in total

1.  Parotid gland-recovery after radiotherapy in the head and neck region--36 months follow-up of a prospective clinical study.

Authors:  Jeremias Hey; Juergen Setz; Reinhard Gerlach; Martin Janich; Guido Hildebrandt; Dirk Vordermark; Christian R Gernhardt; Thomas Kuhnt
Journal:  Radiat Oncol       Date:  2011-09-27       Impact factor: 3.481

2.  Factors influencing the parotid function in nasopharyngeal carcinoma treated with parotid-sparing radiotherapy.

Authors:  Wen-Shan Liu; Steve Pai-Hsun Lee; Jong-Kang Lee; Mao-Chang Su; Gin-Den Chen; Hong-Shen Lee; Huei Lee
Journal:  Jpn J Clin Oncol       Date:  2006-09-28       Impact factor: 3.019

3.  Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.

Authors:  Angel I Blanco; K S Clifford Chao; Issam El Naqa; Gregg E Franklin; Konstantin Zakarian; Milos Vicic; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

4.  Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN).

Authors:  Carlos A Narvaez; Steven E Schild; Stefan Janssen; Ursula Schroeder; Karl L Bruchhage; Samer G Hakim; Dirk Rades
Journal:  Anticancer Res       Date:  2021-01       Impact factor: 2.480

5.  Long-term oral effects in patients treated with radiochemotherapy for head and neck cancer.

Authors:  Aline Lima da Silva Deboni; Adelmo José Giordani; Nilza Nelly Fontana Lopes; Rodrigo Souza Dias; Roberto Araujo Segreto; Siri Beier Jensen; Helena Regina Comodo Segreto
Journal:  Support Care Cancer       Date:  2012-03-13       Impact factor: 3.603

6.  Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy.

Authors:  Dirk Rades; Fabian Fehlauer; Junes Wroblesky; Dirk Albers; Steven E Schild; Rainer Schmidt
Journal:  Oral Oncol       Date:  2006-09-26       Impact factor: 5.337

7.  Risk Factors for Xerostomia Following Radiotherapy of Head-and-Neck Cancers.

Authors:  Britta Warwas; Florian Cremers; Karsten Gerull; Anke Leichtle; Karl L Bruchhage; Samer G Hakim; Steven E Schild; Dirk Rades
Journal:  Anticancer Res       Date:  2022-05       Impact factor: 2.480

8.  Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients.

Authors:  Michael K M Kam; Sing-Fai Leung; Benny Zee; Ricky M C Chau; Joyce J S Suen; Frankie Mo; Maria Lai; Rosalie Ho; Kin-yin Cheung; Brian K H Yu; Samuel K W Chiu; Peter H K Choi; Peter M L Teo; Wing-hong Kwan; Anthony T C Chan
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

9.  Preservation of quality of life after intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: results of a prospective longitudinal study.

Authors:  Anne S McMillan; Edmond H N Pow; Dora L W Kwong; May C M Wong; Jonathan S T Sham; Lucullus H T Leung; W Keung Leung
Journal:  Head Neck       Date:  2006-08       Impact factor: 3.147

10.  Prospective longitudinal assessment of parotid gland function using dynamic quantitative pertechnate scintigraphy and estimation of dose-response relationship of parotid-sparing radiotherapy in head-neck cancers.

Authors:  Tejpal Gupta; Chandni Hotwani; Sadhana Kannan; Zubin Master; Venkatesh Rangarajan; Vedang Murthy; Ashwini Budrukkar; Sarbani Ghosh-Laskar; Jai Prakash Agarwal
Journal:  Radiat Oncol       Date:  2015-03-15       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.